• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

自身免疫性胆汁淤积性肝病中的肌少症性骨病:病因、治疗及挑战。

Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.

机构信息

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele 20090, Milan, Italy.

出版信息

World J Gastroenterol. 2022 Apr 14;28(14):1430-1443. doi: 10.3748/wjg.v28.i14.1430.

DOI:10.3748/wjg.v28.i14.1430
PMID:35582674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9048470/
Abstract

Primary biliary cholangitis and primary sclerosing cholangitis (PSC) are the most common cholestatic liver diseases (CLD) in adults and are both characterized by an immune pathogenesis. While primary biliary cholangitis is a model autoimmune disease, with over 90% of patients presenting very specific autoantibodies against mitochondrial antigens, PSC is considered an immune mediated disease. Osteoporosis is the most common bone disease in CLD, resulting in frequent fractures and leading to significant morbidity. Further, sarcopenia is emerging as a frequent complication of chronic liver diseases with a significant prognostic impact and severe implications on the quality of life of patients. The mechanisms underlying osteoporosis and sarcopenia in CLD are still largely unknown and the association between these clinical conditions remains to be dissected. Although timely diagnosis, prevention, and management of osteosarcopenia are crucial to limit the consequences, there are no specific guidelines for management of osteoporosis and sarcopenia in patients with CLD. International guidelines recommend screening for bone disease at the time of diagnosis of CLD. However, the optimal monitoring strategies and treatments have not been defined yet and vary among centers. We herein aim to comprehensively outline the pathogenic mechanisms and clinical implications of osteosarcopenia in CLD, and to summarize expert recommendations for appropriate diagnostic and therapeutic approaches.

摘要

原发性胆汁性胆管炎和原发性硬化性胆管炎(PSC)是成人中最常见的胆汁淤积性肝病(CLD),两者均以免疫发病机制为特征。虽然原发性胆汁性胆管炎是一种典型的自身免疫性疾病,超过 90%的患者针对线粒体抗原存在非常特异性的自身抗体,但 PSC 被认为是一种免疫介导的疾病。骨质疏松症是 CLD 中最常见的骨骼疾病,导致频繁骨折,并导致显著的发病率。此外,肌肉减少症正成为慢性肝病的常见并发症,对患者的预后有显著影响,并严重影响其生活质量。CLD 中骨质疏松症和肌肉减少症的发病机制在很大程度上仍不清楚,这些临床情况之间的关联仍有待分析。尽管及时诊断、预防和管理骨质疏松症和肌肉减少症对于限制其后果至关重要,但目前尚无针对 CLD 患者骨质疏松症和肌肉减少症管理的具体指南。国际指南建议在 CLD 诊断时筛查骨骼疾病。然而,尚未确定最佳的监测策略和治疗方法,并且在各个中心之间存在差异。本文旨在全面概述 CLD 中骨质疏松症和肌肉减少症的发病机制和临床意义,并总结专家对适当诊断和治疗方法的建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea9a/9048470/6b2965969cd0/WJG-28-1430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea9a/9048470/6b2965969cd0/WJG-28-1430-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea9a/9048470/6b2965969cd0/WJG-28-1430-g001.jpg

相似文献

1
Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges.自身免疫性胆汁淤积性肝病中的肌少症性骨病:病因、治疗及挑战。
World J Gastroenterol. 2022 Apr 14;28(14):1430-1443. doi: 10.3748/wjg.v28.i14.1430.
2
Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis.自身免疫性胆道疾病:原发性胆汁性胆管炎和原发性硬化性胆管炎。
Pathologica. 2021 Jun;113(3):170-184. doi: 10.32074/1591-951X-245.
3
Variant and Specific Forms of Autoimmune Cholestatic Liver Diseases.自身免疫性胆汁淤积性肝病的变异和特殊形式。
Arch Immunol Ther Exp (Warsz). 2019 Aug;67(4):197-211. doi: 10.1007/s00005-019-00550-9. Epub 2019 Jun 5.
4
Making Sense of Autoantibodies in Cholestatic Liver Diseases.胆汁淤积性肝病相关自身抗体的临床解读
Clin Liver Dis. 2016 Feb;20(1):33-46. doi: 10.1016/j.cld.2015.08.003. Epub 2015 Oct 9.
5
Bone disorders in cholestatic liver diseases.胆汁淤积性肝病中的骨病
Forum (Genova). 1998 Jan-Mar;8(1):28-38.
6
[Autoimmune liver diseases and their overlap syndromes].[自身免疫性肝病及其重叠综合征]
Praxis (Bern 1994). 2006 Sep 6;95(36):1363-81. doi: 10.1024/1661-8157.95.36.1363.
7
Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis.原发性胆汁性肝硬化、原发性硬化性胆管炎和自身免疫性胆管炎。
Clin Liver Dis. 2000 Feb;4(1):97-113. doi: 10.1016/s1089-3261(05)70098-2.
8
UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER.巴西肝病学会关于自身免疫性肝病诊断与管理的推荐更新
Arq Gastroenterol. 2019 Aug 13;56(2):232-241. doi: 10.1590/S0004-2803.201900000-43.
9
Clinical management of autoimmune biliary diseases.自身免疫性胆道疾病的临床管理。
J Autoimmun. 2013 Oct;46:88-96. doi: 10.1016/j.jaut.2013.06.014. Epub 2013 Jul 13.
10
[Cholestatic liver diseases].[胆汁淤积性肝病]
Ther Umsch. 2004 Aug;61(8):521-7. doi: 10.1024/0040-5930.61.8.521.

引用本文的文献

1
Osteosarcopenia: epidemiology, molecular mechanisms, and management.骨少肌少症:流行病学、分子机制及管理
Front Endocrinol (Lausanne). 2025 Aug 28;16:1577758. doi: 10.3389/fendo.2025.1577758. eCollection 2025.
2
Sarcopenia-A Valuable Imaging Biomarker for Disease Progression in Patients With Primary Sclerosing Cholangitis (PSC)?肌肉减少症——原发性硬化性胆管炎(PSC)患者疾病进展的一种有价值的影像学生物标志物?
Liver Int. 2025 Oct;45(10):e70328. doi: 10.1111/liv.70328.
3
Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.

本文引用的文献

1
Sarcopenia as a prognostic indicator of liver cirrhosis.肌肉减少症作为肝硬化的预后指标。
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):8-10. doi: 10.1002/jcsm.12869. Epub 2021 Nov 23.
2
Sarcopenia in chronic liver disease: easy to diagnose but hard to treat.慢性肝病中的肌肉减少症:易诊断但难治疗。
Liver Int. 2020 Nov;40(11):2627-2629. doi: 10.1111/liv.14690.
3
Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis.原发性胆汁性胆管炎患者的骨质疏松症、肌少症、椎体骨折和骨肌减少症之间的关系。
肠道、骨骼与肌肉:炎症性肠病中的骨肌减少三联征
Intest Res. 2025 Jul;23(3):254-289. doi: 10.5217/ir.2024.00185. Epub 2025 Apr 29.
4
Multi-modal molecular determinants of clinically relevant osteoporosis subtypes.临床相关骨质疏松症亚型的多模态分子决定因素。
Cell Discov. 2024 Mar 12;10(1):28. doi: 10.1038/s41421-024-00652-5.
5
Prevalence and risk factors of osteoporosis detected by dual-energy X-ray absorptiometry among Chinese patients with primary biliary cholangitis.原发性胆汁性胆管炎患者双能 X 射线吸收法检测骨质疏松症的患病率和危险因素。
World J Gastroenterol. 2023 Aug 7;29(29):4580-4592. doi: 10.3748/wjg.v29.i29.4580.
Eur J Gastroenterol Hepatol. 2021 May 1;33(5):731-737. doi: 10.1097/MEG.0000000000001791.
4
Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.肌少症作为不可切除肝细胞癌患者行单纯经动脉栓塞治疗后生存的预测因子。
PLoS One. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371. eCollection 2020.
5
Effects of Branched-Chain Amino Acid (BCAA) Supplementation on the Progression of Advanced Liver Disease: A Korean Nationwide, Multicenter, Prospective, Observational, Cohort Study.支链氨基酸(BCAA)补充对晚期肝病进展的影响:一项韩国全国性、多中心、前瞻性、观察性队列研究。
Nutrients. 2020 May 15;12(5):1429. doi: 10.3390/nu12051429.
6
Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges.原发性胆汁性胆管炎中的骨质疏松症:患病率、影响及管理挑战
Clin Exp Gastroenterol. 2020 Jan 15;13:17-24. doi: 10.2147/CEG.S204638. eCollection 2020.
7
Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial.利塞膦酸钠治疗食管静脉曲张和肝硬化患者的安全性和有效性:一项非随机临床试验。
Sci Rep. 2019 Dec 12;9(1):18958. doi: 10.1038/s41598-019-55603-y.
8
The Joint Occurrence of Osteoporosis and Sarcopenia (Osteosarcopenia): Definitions and Characteristics.骨质疏松症和肌少症(Osteosarcopenia)的共同发生(Joint Occurrence of Osteoporosis and Sarcopenia):定义和特征。
J Am Med Dir Assoc. 2020 Feb;21(2):220-225. doi: 10.1016/j.jamda.2019.09.005. Epub 2019 Oct 25.
9
Letter to the Editor: Bone Health and Denosumab Treatment in Autoimmune Liver Diseases: A Possible Involvement of Physical Activity.
Hepatology. 2020 Mar;71(3):1131-1132. doi: 10.1002/hep.31001. Epub 2020 Mar 5.
10
Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.3年地诺单抗治疗自身免疫性肝病患者骨质疏松症的疗效与安全性
Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. Epub 2019 Oct 10.